In contrast, mass spectrometry and immunoassay assessments of p-tau217 had quite similar distributions across diagnostic groups, except for one outlier with a non-AD neurodegenerative disease with high p-tau values assessed with mass spectrometry (but not with immunoassays) in the TRIAD cohort. This evidence concerns the gene MAPT and Alzheimer disease.